Fundraising FoxSamsara BioCapital — 2022 Investments
7 investments dated 2022 · listed companies and verified rows first · show all
Mineralys Therapeutics is a clinical-stage pharmaceutical company developing lorundrostat, a treatment targeting dysregulated aldosterone.
BiotechHealthtechRadnor, US
Eric Warren(Chief Commercial Officer)inAlex Gold(Chief Medical Officer)inAdam Levy(Executive Officer)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Founder & former CEO / Board Director)Olivier Litzka(Director)in
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAndera PartnersHBM Healthcare InvestmentsHBM PartnersSR One Capital ManagementYsios CapitalAdams Street Partners+3 more
Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms.
AI & Machine LearningBiotechDeep TechBoston, US
Richard Young, Ph.D.(Director)inAnthony Hyman, Ph.D.(Director)Tony Hyman(Scientific Co-founder)Rick Young(Scientific Co-founder)Elisabeth Leiderman(Executive Officer)inIsaac Klein, M.D., Ph.D.(Executive Officer)
Co-investorsARCH Venture PartnersEcoR1 CapitalGeneral Catalyst6 Dimensions CapitalInnovation EndeavorsLeaps by Bayer+6 more
.png)
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
BiotechCambridge, US
Nancy Simonian(CEO)Peter Wirth(Director)Mark Alles(Director)Philip Sharp(Director)Richard A. Young(Director)Sue Gail Eckhardt(Director)
Board seatSrinivas Akkaraju· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalAlexandriaAlly Bridge GroupBain Capital+11 more
Alpha-9 is a clinical-stage radiopharmaceutical company developing a portfolio of targeted molecules to treat cancer cells with precision.
BiotechLongevityMedical DevicesBoston, US
Co-investorsFrazier Life SciencesWUTIF CapitalAscenta CapitalBiotechnology Value FundLightspeed Venture PartnersLongitude Capital+1 more
Dewpoint Innovations develops functional nanostructured polymeric surfaces for atmospheric water capture, technology originating from PhD research at the University of Sydney.
CleantechClimate TechDeep TechNew Materials
Chiara Neto(Founder & Advisor (Chief Scientific Officer))inMing Chiu(Founder & CTO)in
Co-investorsImpact Ventures Management Pty LtdPacific Channel3E Bioventures CapitalARCH Venture PartnersEcoR1 CapitalGeneral Catalyst+3 more
Simcha is a biotechnology company developing new cancer medicines based on immune biology research.
BiotechHealthtechNew Haven, US
Aaron Ring(Executive Officer, Director)inBeatrice McQueen(Chief Operating Officer)inSanuj Ravindran(Chief Executive Officer)Jeremy Barton(Chief Medical Director)Hirdesh Uppal(Senior Vice President Translational Research and Development Sciences)Joseph Catino(Executive Officer)
Co-investorsConnecticut InnovationsPfizer Venture InvestmentsSR One Capital ManagementAxial VCBiotechnology Value FundRock Springs Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Link Cell Therapies
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.